

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2001262141 B2**

(54) Title
Use of cdp-choline for the treatment of alcohol withdrawal syndrome

(51)⁷ International Patent Classification(s)
A61K 031/00

(21) Application No: **2001262141** (22) Date of Filing: **2001.03.28**

(87) WIPO No: **WO01/72288**

(30) Priority Data

(31) Number	(32) Date	(33) Country
200000765	2000.03.29	ES

(43) Publication Date: **2001.10.08**

(43) Publication Journal Date: **2001.12.20**

(44) Accepted Journal Date: **2005.03.10**

(71) Applicant(s)
Ferrer Internacional, S.A.

(72) Inventor(s)
Ortiz, Jose A; Castello, Josep M; Raga, Manuel M.; Torres, Jesus; Agut, Julian; Lozano, Rafael; Ramentol, Jorge; Foguet, Rafael

(74) Agent / Attorney
Shelston IP, Level 21 60 Margaret Street, Sydney, NSW, 2000

(56) Related Art
Renshaw PF et al. "Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report" Psychopharmacology (1999) Vol. 142(2): 132-138

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72288 A3

- (51) International Patent Classification⁷: **A61K 31/70**,
A61P 25/32
- (74) Agents: **KINZEBACH, Werner** et al.; Reitstötter, Kinze-
bach & Partner, Sternwartstr. 4, 81679 München (DE).
- (21) International Application Number: PCT/EP01/03536
- (22) International Filing Date: 28 March 2001 (28.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
P2000 00765 29 March 2000 (29.03.2000) ES
- (71) Applicant (for all designated States except US): **FERRER
INTERNACIONAL, S.A.** [ES/ES]; Gran Vía Carlos III,
94, E-08028 Barcelona (ES).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- (88) Date of publication of the international search report:
10 May 2002
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **FOGUET, Rafael**
[ES/ES]; Lluçanès, 8, E-08028 Barcelona (ES). **RAMEN-
TOL, Jorge** [ES/ES]; Lleó XIII 2, E-08022 Barcelona
(ES). **LOZANO, Rafael** [ES/ES]; Bertran 45, E-08023
Barcelona (ES). **AGUT, Julián** [ES/ES]; Riera 13E,
E-08190 Sant Cugat (ES). **TORRES, Jesús** [ES/ES];
Pstg. Forasté 4bis, E-08017 Barcelona (ES). **RAGA,
Manuel M.** [ES/ES]; Sors 17-21, E-08024 Barcelona
(ES). **CASTELLÓ, Josep M.** [ES/ES]; Av. Princep
d'Asturies, 35, E-08034 Barcelona (ES). **ORTIZ, José A.**
[ES/ES]; Còrscga, 429m, E-08037 Barcelona (ES).

WO 01/72288 A3

(54) Title: USE OF CDP-CHOLINE FOR THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME

(57) Abstract: The invention relates to the use of CDP-Choline or its pharmaceutically acceptable salts for the preparation of a medicinal product for the treatment of alcohol withdrawal syndrome at daily doses equivalent to 0.5-2g of free CDP-Choline.

USE OF CDP-CHOLINE FOR THE TREATMENT OF ALCOHOL WITHDRAWAL
SYNDROME

DESCRIPTION

5

The present invention relates to the use of CDP-choline for the treatment of alcohol withdrawal syndrome.

10

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

15

20

The toxic effects of alcohol on central nervous system are basically exerted on neuronal membrane and synapses (Leonard B. E., *Alcohol Alcohol.*, 1986: 21(4), 325-338). Histological alterations of neuronal structure consist in a lesser branching of hippocampus nerve cells and Purkinje's cells. Comparison of brains from healthy subjects with those from alcoholic patients revealed a lesser branching of pyramidal neuronal basal dendrites in upper cerebral cortex and motor cortex (Ledig M. and Mandel P., *M S-Medecine Sciences*, 1988: 4(6), 352-357).

Chronic alcohol abuse has also been reported to impair dopamine receptor sensitivity. This effect is probably related to changes in neuronal membrane fluidity and in the number and functionality of receptors, as well as to a decrease in acetylcholine reuptake and dopamine deficiency (Carlen P. L. and col., *Ann. Neurol.*, 1981: 9(1), 84-86).

CDP-choline (cytidine diphosphate choline, Citicoline) is a key intermediate in the synthesis of structural phospholipids present in the neuronal membrane (Kennedy E. P. and Weiss S. B., *J. Biol. Chem.*, 1956; 222, 193-214) and plays an important role in its formation and repair when the phospholipidic structure is damaged by endogenous or exogenous causes involving a decrease in cytidine and choline uptake.

The administration of CDP-choline enhances dopamine synthesis and release (Martinet M. et al., *Biochem. Pharmacol.*, 1981: 30(5), 539-541) as well as choline and acetylcholine brain levels. The administration of repeated doses of CDP-choline produces an increase of brain phospholipid levels, which is secondary to an increase of cytidine and choline plasma levels (Agut J. et al., *Ann. New York Acad. Sci.*, 1993: 695, 318-320).

The present invention provides the use of CDP-choline or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of alcohol withdrawal syndrome.

5

The present invention also provides a method for the treatment of alcohol withdrawal syndrome comprising administering to an alcoholic patient in need thereof an effective amount of CDP-choline or of a pharmaceutically acceptable salt thereof.

10

Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".


15

Surprisingly, the applicants have found out that the administration of CDP-choline to alcoholic patients reduces the duration and intensity of their withdrawal symptoms and induces an evident recovery in a significant proportion of patients.

20

- 2b -

The use of CDP-choline according to the present invention, which includes a method for treating alcohol withdrawal syndrome, comprises the administration of an effective



amount of CDP-choline or a pharmaceutically acceptable salt thereof to an alcoholic patient.

According to the present invention, CDP-choline is administered as free compound or as a pharmaceutically acceptable salt, whether in anhydrous or hydrated form, conveniently mixed with pharmaceutical carriers and/or excipients, to humans at daily doses of 0.5 to 2 g inclusive in free CDP-choline, preferably from 0.5 to 1 g inclusive, both orally and parentally. Pharmaceutically acceptable salts of CDP-choline include its alkaline or alkaline earth salts, such as its sodium, potassium, calcium and magnesium salts or its acid addition salts with a mineral or organic acid, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, citric acid, lactic acid, malonic acid, tartaric acid, acrylic acid, metacrylic acid, malic acid, maleic acid, fumaric acid, benzoic acid, salicylic acid, cinnamic acid, methane sulphonc acid, benzenesulphonic acid, p-toluensulphonic acid and nicotinic acid.

CDP-choline and its salts, whether as anhydrous or hydrated substances, under the invention may be administered orally in the form of tablets, capsules, powder, granules, cachets, lozenges, solution, suspension, emulsion, syrup, gel and the like; or parenterally in the form of solution,

suspension, emulsion or the like for intravenous or intramuscular injection.

EXAMPLES

The present invention is illustrated by the Examples that follow. Those skilled in the art will be able to make any change provided the specific embodiment of the invention is not modified and, therefore, the invention is not limited to the specific details of the Examples.

EXAMPLE 1: 500 mg tablets

CDP-choline, sodium salt	522.5 mg
Talc	30.0 mg
Magnesium stearate	3.0 mg
Silicon dioxide	2.5 mg
Croscarmellose sodium	20.0 mg
Corn starch	20.0 mg
Microcrystalline cellulose s.q.	780.0 mg

EXAMPLE: 25% oral solution

CDP-choline, sodium salt	26.12 g
70% Sorbitol	20.00 g
Methyl p-hydroxybenzoate	0.16 g

Propyl p-hydroxybenzoate	0.04 g
Disodium citrate	0.60 g
Saccharin sodium	0.02 g
Strawberry essence	0.04 g
Red Punzo 4R	0.50 mg
Anhydrous citric acid	0.05 g
Purified water s.q.	100.00 ml

EXAMPLE 3: Solution for injection

CDP-choline, sodium salt	522.50 mg
Hydrochloric acid, pH 6.0-6.5 s.q.	
Water for injection s.q.	4.00 ml

EXAMPLE 4 : Open clinical study of CDP-choline in alcohol withdrawal syndrome

The progress of alcohol withdrawal syndrome was assessed in an open study conducted in 197 patients. CDP-choline was administered at doses of 500 mg/d i.m. or 600 mg/d p.o. for 60 days. At 30 and 60 days following treatment, significant differences ($p < 0.001$) were observed in the assessments performed. At 60 days, 55.83% of patients had given up drinking alcohol and 31.97% of patients drank much less. A significant improvement was observed on anxiety, tremor, disorientation, insomnia, dysarthria, tendency to suicide and neuritic pains.

EXAMPLE 5: Open, randomized, comparative clinical study of CDP-choline in alcohol withdrawal syndrome versus clomethiazole and vitamin B.

5 An open, randomized and comparative study on the conventional therapy of alcohol withdrawal syndrome was conducted in 40 patients. Patients were randomly distributed in two groups of 20. One of the groups was used as control and received clomethiazole and vitamin B₁, B₆ and
10 B₁₂. This treatment regimen was maintained for 8 days, and then patients were given diazepam until completion of treatment (60 days). The other group of patients received the same treatment regimen plus CDP-choline 500 mg i.m. every 12 h for the first 30 days and CDP-choline 200 mg
15 p.o. every 8 h for the remaining 30 days. The patients who received CDP-choline plus the conventional therapy showed significant differences versus control at 30 days following treatment in tremor incidence ($p < 0.05$), cramps ($p < 0.05$),
asthenia ($p < 0.05$), emotional lability ($p < 0.01$), nervousness
20 ($p < 0.05$) and social withdrawal ($p < 0.05$).

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. The use of CDP-choline or of a pharmaceutically acceptable salt thereof for the preparation of a medicament
5 for the treatment of alcohol withdrawal syndrome.

2. The use according to claim 1 in which the pharmaceutically acceptable salts of CDP-choline are its alkaline or alkaline earth salts or its salts with mineral or organic acids such as hydrochloric acid, hydrobromic
10 acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, citric acid, lactic acid, malonic acid, tartaric acid, acrylic acid, metacrylic acid, malic acid, maleic acid, fumaric acid, benzoic acid, salicylic acid, cinnamic acid, methane sulphononic acid,
15 benzenesulphonic acid, p-toluensulphonic acid and nicotinic acid in anhydrous or hydrated form.

3. The use according to claim 1 or 2 at daily doses in equivalent amounts of free CDP-choline ranging from 0.5 to
2 g.

20 4. The use according to claim 3, wherein the doses range from 0.5 to 1 g.

5. A method for the treatment of alcohol withdrawal syndrome comprising administering to an alcoholic patient in need thereof an effective amount of CDP-choline or of a
25 pharmaceutically acceptable salt thereof.

6. Use of CDP-chloine or a pharmaceutically acceptable salt thereof, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples.

5 7. A method for the treatment of alcohol withdrawal syndrome substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples.

10 DATED this 18th Day of September 2003
BALDWIN SHELSTON WATERS
Attorneys for: FERRER INTERNACIONAL, S.A.